L’Occitane has released its third quarter 2024 results, which showed net sales were €843.4 million, representing growth of 19.5% at reported rates and 24.6% at constant rates. Net sales for nine months ended December, 31, 2023 were €1,915.3 million, representing 18.9% growth at reported rates and 24.8% growth at constant rates.
L’Occitane en Provence
Net sales in the third quarter were €491.5 million, as compared to €506.3 million in the previous year.
Net sales for nine months were €1,087.2 million, as compared to €1,116.6 million in the previous year.
Elemis
Net sales for the third quarter were €87.7 million, as compared to €76.4 million in the previous year.
In Q3, the United Kingdom and the United States grew 23.2% and 19.4% respectively at constant rates.
Net sales for nine months were €196.8 million, as compared to €181.5 million in the previous year.
Sol de Janeiro
Net sales for the third quarter were €204.4 million, as compared to €68.3 million in the previous year.
Net sales for nine months were €474.4 million, as compared to €166.8 million in the previous year.
The brand saw triple-digit growth across all geographies, driven by a record-breaking holiday season, the debut of a new body cream Delicia Drench Body Butter and an accompanying fragrance mist, and a strategic expansion of its distribution with a significant multi-brand partner in the U.S.
André Hoffmann, vice-chairman and CEO of L’Occitane, said, “We delivered a decent holiday season, which enabled us to maintain our growth momentum and relative outperformance in the premium beauty market in China and other key markets. It was also pleasing to see Elemis return to growth in light of our ongoing premiumization strategy to support its long-term profitability. We will continue to build on the accelerating growth of Sol de Janeiro as we steadily expand its product and category range, and the scale and reach of its distribution. We will also further build on the healthy growth of other brands, including our recently acquired luxury home fragrance brand, Dr. Vranjes Firenze, to round out our portfolio.”
